Efficacy and safety of filgotinib as induction and maintenance therapy for Crohn's disease (DIVERSITY): a phase 3, double-blind, randomised, placebo-controlled trial.

Efficacy and safety of filgotinib as induction and maintenance therapy for Crohn's disease (DIVERSITY): a phase 3, double-blind, randomised, placebo-controlled trial. Lancet Gastroenterol Hepatol. 2025 02; 10(2):138-153.

View in: PubMed

subject areas

Adolescent
Adult
Aged
Crohn Disease
Double-Blind Method
Female
Humans
Induction Chemotherapy
Maintenance Chemotherapy
Male
Middle Aged
Patient Reported Outcome Measures
Pyridines
Remission Induction
Treatment Outcome
Triazoles
Young Adult

authors with profiles

David Rubin